Treatment and outcome of biopsy-proven fulminant myocarditis in adults

Fulminant myocarditis may be rapidly fatal with severe haemodynamic compromise in previously healthy patients. We reviewed our experience with eight cases of biopsy-proven fulminant myocarditis (seven cases with lymphocytic myocarditis and one with eosinophilic myocarditis). Immunosuppression was gi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2006-06, Vol.110 (3), p.405-406
Main Authors: Chau, Elaine M.C., Chow, Wing-Hing, Chiu, Clement S.W., Wang, Elaine
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Biopsy
Cardiology. Vascular system
Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care
Endomyocardial biopsy
Female
Fulminant myocarditis
Heart
Humans
Immunosuppression
Intensive care medicine
Male
Mechanical circulatory support
Medical sciences
Middle Aged
Myocarditis - diagnosis
Myocarditis - pathology
Myocarditis - surgery
Myocarditis - therapy
Myocarditis. Cardiomyopathies
Prognosis
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fulminant myocarditis may be rapidly fatal with severe haemodynamic compromise in previously healthy patients. We reviewed our experience with eight cases of biopsy-proven fulminant myocarditis (seven cases with lymphocytic myocarditis and one with eosinophilic myocarditis). Immunosuppression was given in seven out of eight cases. Mechanical circulatory support was required in 50% of the patients. Time from onset of illness to recovery of ventricular function varied from 12 to 17 days. All except one patient were alive at a mean follow-up of 4.4 years after the acute illness. Patients with acute fulminant myocarditis should be treated aggressively with immunosuppression and, if necessary, mechanical circulatory support during the first 2 to 3 weeks of the illness because of the reversible nature of this illness and good long-term prognosis.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2005.07.082